AG
ATRA icon

Aperio Group’s Atara Biotherapeutics ATRA Stock Holding History

Aperio Group’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$508K Sell
1,036
-215
-17% -$99.2K ﹤0.01% 1959
2020
Q3 		$405K Buy
1,251
+583
+87% +$199K ﹤0.01% 1929
2020
Q2 		$243K Sell
668
-12
-2% -$3.03K ﹤0.01% 2111
2020
Q1 		$145K Buy
+680
New +$216K ﹤0.01% 2152
2019
Q3 		– Sell
-125
Closed -$63K – 2342
2019
Q2 		$63K Buy
+125
New +$88.2K ﹤0.01% 2488

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Aperio Group's ATRA Position: Q4 2020 in Review

Aperio Group reduced its Atara Biotherapeutics (ATRA) stake by 17% in Q4 2020, selling an estimated $99.2K and leaving 1,036 shares worth $508K. The position accounts for ﹤0.01% of the portfolio, ranked #1959.

Aperio Group first reported a position in ATRA in Q2 2019 and has held it in 5 quarters since. 148 funds tracked by Wall St. Rank hold ATRA as of Q4 2020.

  • Aperio Group held 1,036 shares of Atara Biotherapeutics worth $508K as of Q4 2020.
  • Aperio Group sold 215 Atara Biotherapeutics shares in Q4 2020, an estimated $99.2K.
  • Atara Biotherapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1959 holding.
  • Aperio Group first reported a position in Atara Biotherapeutics in Q2 2019 and has held it in 5 quarters since.
  • 148 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.